Anti-CRP-positive patients with SLE tended to be positive for other autoantibodies (aPL and antibodies to double-stranded DNA) and to have elevated serum CRP and C3 hypocomplementemia. About 50% ...

an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. A phase 2 trial of iptacopan in patients with the rare kidney disease C3 ...